Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease

被引：0
|
作者：
Andrew P. Yu
Scott Johnson
Si-Tien Wang
Pavel Atanasov
Jackson Tang
Eric Wu
Jingdong Chao
Parvez M. Mulani
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Abbott Laboratories,undefined
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Infliximab; Adalimumab; Probabilistic Sensitivity Analysis; Tumour Necrosis Factor Antagonist; Infliximab Maintenance Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn’s disease.
引用
收藏
页码：609 / 621
页数：12
相关论文
共 50 条
  • [41] Effect of upadacitinib on extraintestinal manifestations in patients with moderately to severely active Crohn's disease
    Wright, Emily K.
    Colombel, Jean-Frederic
    Hudesman, David
    Cao, Qian
    Ghosh, Subrata
    Reinisch, Walter
    Lacerda, Ana
    Dubcenco, Elena
    Doshi, Chirag
    Anyanwu, Samuel
    Feng, Tian
    Rubin, David
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 159 - 160
  • [42] COST-EFFECTIVENESS ANALYSIS OF ADALIMUMAB VS. CERTOLIZUMAB MAINTENANCE THERAPIES FOR MODERATE TO SEVERE CROHN'S DISEASE
    Johnson, S.
    Kaltenboeck, A.
    Horn, C.
    Mulani, P.
    Majethia, S.
    Chao, J.
    VALUE IN HEALTH, 2009, 12 (03) : A59 - A59
  • [43] Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease
    Loftus, Edward V., Jr.
    Johnson, Scott J.
    Yu, Andrew P.
    Wu, Eric Q.
    Chao, Jingdong
    Mulani, Parvez M.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (11) : 1302 - 1309
  • [44] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    GASTROENTEROLOGY, 2022, 162 (03) : S15 - S15
  • [45] Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease
    Feagan, Brian
    Tan, Seng
    Malone, Daniel
    Hinojosa, Joaquin
    Brown, Martin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S392 - S392
  • [46] Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn's disease
    Blumenstein, I.
    Torres, J.
    Ma, C.
    Lindsay, J. O.
    Ungaro, R.
    Thin, L.
    Lacerda, A. P.
    Anyanwu, S. I.
    Garrison, A.
    Ford, S.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : II000 - I1001
  • [47] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S15 - S15
  • [48] Estimation of induction and maintenance costs of Infliximab, Adalimumab and Certolizumab Pegol in managing Crohn's Disease
    Feagan, B.
    Tan, S.
    Malone, D.
    Hinojosa, J.
    Brown, M.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S33 - S33
  • [49] Adalimumab maintenance therapy in infliximab exposed pediatric Crohn's disease; a Dutch nationwide survey
    Cozijnsen, M.
    Duif, V.
    Kokke, F.
    Kindermann, A.
    van Rheenen, P.
    de Meij, T.
    Schaart, M.
    Damen, G.
    Norbruis, O.
    Pelleboer, R.
    Van den Neucker, A.
    van Wering, H.
    Hummel, T.
    Escher, J.
    de Ridder, L.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S305 - S306
  • [50] Is scheduled maintenance treatment with infliximab cost effective in patients with Crohn's disease?
    Lindsay, James O.
    Punekar, Yogesh
    Morris, James
    Chung-Faye, Guy
    GASTROINTESTINAL ENDOSCOPY, 2008, 67 (05) : AB318 - AB318
12345